BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/29/2026 8:41:37 AM | Browse: 1 | Download: 10
 |
Received |
|
2025-12-02 02:25 |
|
Peer-Review Started |
|
2025-12-02 02:25 |
|
First Decision by Editorial Office Director |
|
2025-12-19 08:11 |
|
Return for Revision |
|
2025-12-19 08:11 |
|
Revised |
|
2026-02-10 03:32 |
|
Publication Fee Transferred |
|
2026-02-11 23:03 |
|
Second Decision by Editor |
|
2026-04-07 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-07 10:23 |
|
Articles in Press |
|
2026-04-07 10:23 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-18 04:05 |
|
Publish the Manuscript Online |
|
2026-05-29 08:41 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Review |
| Article Title |
C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Arun Chutani, Sayna Norouzi and Edgar V Lerma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Arun Chutani, Assistant Professor, FACP, FASN, MD, Renal Medicine, UMass Chan Medical School, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, United States. docarun26@gmail.com |
| Key Words |
C3 glomerulopathy; Alternate pathway; Complement; Iptacopan; Pegcetocoplan |
| Core Tip |
C3 glomerulopathy is the most frequent recurrent glomerular disease after kidney transplantation, with recurrence rates up to 90%. Its pathogenesis is driven by alternative complement pathway dysregulation, influenced by genetic mutations, autoantibodies, monoclonal gammopathy, and transplant-specific triggers such as ischemia-reperfusion injury and viral infections. Histopathology in the allograft often shows subtler C3 deposition compared with native disease, underscoring the need for protocol biopsies. Traditional immunosuppression offers limited benefit, while novel complement-targeted therapies - including factor B inhibitors (iptacopan), C3 inhibitors (pegcetacoplan), and factor D inhibitors - represent a paradigm shift. Early case reports in transplant recipients demonstrate promising outcomes, highlighting the importance of personalized medicine and early intervention to preserve graft survival. |
| Publish Date |
2026-05-29 08:41 |
| Citation |
Chutani A, Norouzi S, Lerma EV. C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms. World J Transplant 2026; 16(2): 117138 |
| URL |
https://www.wjgnet.com/2220-3230/full/v16/i2/117138.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v16.i2.117138 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
